High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C.

AIM To determine whether body weight and/or serum leptin were independent predictors of response to antiviral treatment in patients with chronic hepatitis C. METHODS A retrospective evaluation was performed in 139 patients with chronic hepatitis C treated with interferon (IFN) from 1996 to 2000. Sustained response was defined as negative by hepatitis C virus (HCV) RNA analysis using PCR and normal transaminase at 24 wk after cessation of IFN therapy. Patients who remained positive for HCV RNA at the end of IFN treatment were defined as resistant to IFN therapy. Sex, age, body mass index (BMI) (> or =25 vs <25), complication of diabetes mellitus, serum leptin level (> or =8.0 microg/L vs < 8.0 microg/L), and the stage of liver fibrosis by needle biopsy (F1/F2 vs F3/F4) were examined. RESULTS Sustained response was achieved in 33 patients (23.7%), while others failed to show a response to IFN therapy. Overall, the factors associated with sustained antiviral effects were HCV-RNA load, HCV genotype, serum leptin level, and stage of liver fibrosis evaluated by univariate analysis. BMI was not associated with any therapeutic effect of IFN. Multivariate analysis indicated that HCV-RNA load was a significant risk factor, but among the patients with low viremia (HCV-RNA <100 MU/L), leptin level was an independent risk factor for IFN resistance. Namely, a high level of serum leptin attenuated the effect of IFN on both male and female patients with low viremia. CONCLUSION High serum leptin level is a negative predictor of response to antiviral treatment in chronic hepatitis C with low viremia.

• Publication year

  2006

• Venue

  World Journal of Gastroenterology

• Publication date

  2006-01-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3748/WJG.V12.I4.556PMID 16489668PMCID PMC4066087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Leptin, leptin receptors and the control of body weight.

  2009cited by this paper
• Clearance of serum hepatitis C virus RNA after interferon therapy in relation to virus genotype.

  2008cited by this paper
• Differences Between Interferon-α and-β Treatment for Patients with Chronic Hepatitis C Virus Infection

  2004cited by this paper
• Effect of Obesity on Pharmacokinetics and Biologic Effect of Interferon-alpha in Hepatitis C

  2004cited by this paper
• The severity of liver fibrosis is associated with high leptin levels in chronic Hepatitis C

  2004cited by this paper
• Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan : therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors

  2004cited by this paper
• High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C

  2003cited by this paper
• In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

  2003cited by this paper
• The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C.

  2003cited by this paper
• Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.

  2002cited by this paper
• Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat.

  2002cited by this paper
• Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation.

  2001cited by this paper
• Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

  2001cited by this paper
• Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C

  2000cited by this paper
• Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis.

  2000cited by this paper
• Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

  1999cited by this paper
• Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.

  1999cited by this paper
• Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin.

  1999cited by this paper
• Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

  1999cited by this paper
• Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.

  1997cited by this paper
• Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

  1997cited by this paper
• Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.

  1997cited by this paper
• Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters.

  1996cited by this paper
• Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C

  1995cited by this paper
• Positional cloning of the mouse obese gene and its human homologue

  1995cited by this paper
• Positional cloning of the mouse obese gene and its human homologue

  1994cited by this paper
• Classification of chronic hepatitis: Diagnosis, grading and staging

  1994cited by this paper
• Charting of daily weight pattern reinforces maintenance of weight reduction in moderately obese patients.

  1992cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Tumor Necrosis Factor Increases Serum Leptin Levels in Humans

  year unknowncited by this paper

• Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression

  2020cites this paper
• FACTORS REFRACTORY TO CONVENTIONAL INTERFERON BASED THERAPY IN CHRONIC HEPATITIS C

  2017cites this paper
• Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity

  2016cites this paper
• Interaction of obesity and infections

  2015cites this paper
• Wybrane adipocytokiny i ich potencjalne zastosowanie w kontroli przebiegu przewlekłego wirusowego zapalenia wątroby typu B i C

  2015cites this paper
• The Effect on Gastric Emptying of Telaprevir-Based Triple Therapy for Chronic Hepatitis C Patients

  2015cites this paper
• Serum Leptin, Ferritin and Uric Acid as Predictors of Fibrosis and Sustained Virological Response in Chronic Hepatitis C Patients

  2014cites this paper
• Hepatitis C virus resistance to interferon therapy: an alarming situation

  2014cites this paper
• Serum leptin and plasma ghrelin concentrations in patients with chronic hepatitis C virus with steatosis: Their effect on the response to antiviral therapy

  2014cites this paper
• Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4

  2013cites this paper
• Prognostic value of serum ferritin and leptin in prediction of sustained virological response in chronic HCV patients under peglated interferon and ribavirin therapy

  2013cites this paper
• Independent factors associated with altered plasma active ghrelin levels in HCV‐infected patients

  2013cites this paper
• Serum leptin and ghrelin in chronic hepatitis C patients with steatosis.

  2011cites this paper
• Can exercise be a new approach for chronic hepatitis C?

  2011cites this paper
• Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C

  2009cites this paper
• Die Rolle des Ferroportins bei chronischer Hepatitis C

  2009cites this paper
• Review: Predicting the probable outcome of treatment in HCV patients

  2009cites this paper
• Hepatic steatosis: a benign disease or a silent killer.

  2008cites this paper
• Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime

  2008cites this paper
• Insulin resistance, adipocytokines, and hepatitis C virus infection: A missing link?

  2008cites this paper
• HEPATITIS VIRUS C INFECTION, ADIPOKINES AND HEPATIC STEATO–FIBROSIS

  2008cites this paper
• Impact of host insulin resistance on fibrosis and response to interferon in chronic hepatitis C.

  2008cites this paper
• Reply:

  2008cites this paper
• Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load

  2008cites this paper
• Managing chronic hepatitis C in the difficult-to-treat patient

  2007cites this paper
• An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study

  2007cites this paper